I came to The Cancer Institute of New Jersey (CINJ) in 2007. After studying biological sciences and English literature at Rutgers College and the University of Sussex, Brighton, England, I chose UMDNJ-Robert Wood Johnson for medical school. During this time I also completed a one year Howard Hughes Medical Institute Research Scholar Fellowship, leaving New Jersey to live at the National Institutes of Health for a year of laboratory research. This was followed by an intense, competitive residency in internal medicine at The Mount Sinai Hospital, New York. I then moved further north to New Haven, Connecticut, for a fellowship in medical oncology and hematology at The Yale Cancer Center.
I was thrilled to return to New Jersey when I accepted a position with CINJ/UMDNJ-Robert Wood Johnson Medical School, where I am now an associate professor of medicine. I feel a real commitment toward serving the people of New Jersey, making sure the most cutting edge therapies are easily available to members of our state. Having grown up at the Jersey Shore, I have long understood the risks associated with too much sun exposure, particularly the development of skin cancer. As a member of the Melanoma and Soft Tissue Oncology Program at CINJ, I work collaboratively with radiation oncologists, surgical oncologists, nurses, social workers and other experts to help educate patients about their disease and help them navigate their treatment options.
None of the recent advances in melanoma therapy would have been possible without clinical trials. My research focuses on the development of novel therapies for all types of tumors, with a focus on melanoma, sarcoma, and lung tumors. I have a specific interest in autophagy, a mode of survival for tumors which may possibly be interrupted or blocked, resulting in improved therapeutic outcomes. At a national level, I am part of the Melanoma Committee of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, where I work with other investigators to develop clinical trials for patients with melanoma. I also have several active collaborations with the National Cancer Institute-Cancer Therapy Evaluation Program Investigational Drug Branch, adding even more options to the clinical trial menu of our Developmental Therapeutics Division.
In this age of personalized medicine, my philosophy is to develop an individualized treatment plan for every patient, delivered in a compassionate and supportive setting.
Melanoma, sarcoma, developmental therapeutics
- Member, Alpha Omega Alpha Medical Honor Society
- American Society of Clinical Oncology Merit Award
Member, Alpha Omega Alpha Medical Honor Society
To schedule an appointment call 732-235-8515